Vito Terlizzi

1.8k total citations
90 papers, 932 citations indexed

About

Vito Terlizzi is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Surgery. According to data from OpenAlex, Vito Terlizzi has authored 90 papers receiving a total of 932 indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Pulmonary and Respiratory Medicine, 13 papers in Epidemiology and 8 papers in Surgery. Recurrent topics in Vito Terlizzi's work include Cystic Fibrosis Research Advances (65 papers), Neonatal Respiratory Health Research (41 papers) and Tracheal and airway disorders (31 papers). Vito Terlizzi is often cited by papers focused on Cystic Fibrosis Research Advances (65 papers), Neonatal Respiratory Health Research (41 papers) and Tracheal and airway disorders (31 papers). Vito Terlizzi collaborates with scholars based in Italy, United States and United Kingdom. Vito Terlizzi's co-authors include Giovanni Taccetti, Valeria Raia, Angela Sepe, Giuseppe Castaldo, Maria Rosaria Catania, Antonietta Lambiase, Fabio Rossano, Mariassunta Del Pezzo, Donatello Salvatore and Michela Francalanci and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Vito Terlizzi

80 papers receiving 926 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vito Terlizzi Italy 17 731 98 93 82 60 90 932
Annie Lu Canada 10 497 0.7× 115 1.2× 210 2.3× 297 3.6× 76 1.3× 12 821
Hsin‐Chun Huang Taiwan 18 223 0.3× 120 1.2× 18 0.2× 147 1.8× 53 0.9× 58 800
Sheila G. McKenzie Switzerland 11 890 1.2× 102 1.0× 12 0.1× 115 1.4× 46 0.8× 14 1.1k
Rita Padoan Italy 19 824 1.1× 169 1.7× 7 0.1× 112 1.4× 17 0.3× 80 1.1k
Hara Levy United States 20 682 0.9× 174 1.8× 8 0.1× 243 3.0× 10 0.2× 39 1.1k
T.J. Warke United Kingdom 10 438 0.6× 51 0.5× 30 0.3× 63 0.8× 26 0.4× 13 620
Fabio Majo Italy 14 299 0.4× 117 1.2× 4 0.0× 120 1.5× 16 0.3× 40 568
Guillermo Suárez-Cuartín Spain 15 598 0.8× 158 1.6× 9 0.1× 146 1.8× 6 0.1× 43 926
Taşkın Yurtseven Türkiye 17 121 0.2× 150 1.5× 16 0.2× 56 0.7× 8 0.1× 40 877
Adèle Coriati Canada 14 459 0.6× 25 0.3× 6 0.1× 45 0.5× 12 0.2× 39 677

Countries citing papers authored by Vito Terlizzi

Since Specialization
Citations

This map shows the geographic impact of Vito Terlizzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vito Terlizzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vito Terlizzi more than expected).

Fields of papers citing papers by Vito Terlizzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vito Terlizzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vito Terlizzi. The network helps show where Vito Terlizzi may publish in the future.

Co-authorship network of co-authors of Vito Terlizzi

This figure shows the co-authorship network connecting the top 25 collaborators of Vito Terlizzi. A scholar is included among the top collaborators of Vito Terlizzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vito Terlizzi. Vito Terlizzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Conti, Jessica, Alessia Farinazzo, Luca Rodella, et al.. (2025). Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers. Journal of Cystic Fibrosis. 24(3). 552–561. 2 indexed citations
2.
Salvatore, Donatello, Paola Iacotucci, Angela Pepe, et al.. (2025). Real-world effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients with Phe508del -gating and -residual function genotypes. Respiratory Medicine. 245. 108221–108221. 1 indexed citations
3.
Pepe, Angela, Daniela Dolce, Silvia Campana, et al.. (2025). Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study. Therapeutic Advances in Respiratory Disease. 19. 2703894034–2703894034. 3 indexed citations
4.
Terlizzi, Vito & Miquéias Lopes‐Pacheco. (2025). Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor. Therapeutic Advances in Respiratory Disease. 19. 2703902522–2703902522. 5 indexed citations
5.
Castaldo, Alice, Vincenzo Carnovale, Paola Iacotucci, et al.. (2025). Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction. Scientific Reports. 15(1). 27571–27571. 1 indexed citations
6.
Alicandro, Gianfranco, Vito Terlizzi, Laura Zazzeron, et al.. (2025). Effectiveness of elexacaftor/tezacaftor/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry. Pediatric Research.
7.
Terlizzi, Vito & Philip M. Farrell. (2024). Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians. Current problems in pediatric and adolescent health care. 54(6). 101637–101637. 22 indexed citations
8.
Taccetti, Giovanni, Vito Terlizzi, Silvia Campana, et al.. (2024). Antibiotic treatment of bacterial lung infections in cystic fibrosis. European Journal of Pediatrics. 184(1). 82–82. 1 indexed citations
9.
Melotti, Paola, et al.. (2024). CFTR modulators response of S737F and T465N CFTR variants on patient-derived rectal organoids. Orphanet Journal of Rare Diseases. 19(1). 343–343. 2 indexed citations
10.
Chierico, Federica Del, Alessandra Russo, Pamela Vernocchi, et al.. (2024). Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report. Microorganisms. 12(10). 2059–2059. 1 indexed citations
11.
Terlizzi, Vito, Alice Castaldo, Simone Vespa, et al.. (2024). Non pathological sweat test, pancreatic insufficiency and Cystic Fibrosis: an unusual case in a child with F508del-duplication of exons 1–3 CFTR genotype. BMC Pediatrics. 24(1). 752–752. 1 indexed citations
12.
Terlizzi, Vito, et al.. (2023). Relationship between the strain measures of left atrial function and heart failure worsening. Echocardiography. 40(9). 942–951.
13.
Terlizzi, Vito & Daniela Dolce. (2023). Variability of the sweat test in children with Cystic Fibrosis previously CRMS/CFSPID: A retrospective monocenter experience. Journal of Cystic Fibrosis. 22(3). 496–498. 5 indexed citations
14.
Terlizzi, Vito, et al.. (2023). Stenotrophomonas maltophilia in people with Cystic Fibrosis: a systematic review of prevalence, risk factors and management. European Journal of Clinical Microbiology & Infectious Diseases. 42(11). 1285–1296. 14 indexed citations
15.
16.
Carnovale, Vincenzo, Paola Iacotucci, Vito Terlizzi, et al.. (2022). Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study. Journal of Clinical Medicine. 11(4). 1021–1021. 39 indexed citations
17.
Comegna, Marika, Vito Terlizzi, Donatello Salvatore, et al.. (2021). Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype. Antibiotics. 10(7). 828–828. 21 indexed citations
18.
Carnovale, Vincenzo, Paola Iacotucci, Vito Terlizzi, et al.. (2021). Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype. Respiratory Medicine. 189. 106646–106646. 38 indexed citations
19.
Terlizzi, Vito, Michela Francalanci, Giovanni Taccetti, et al.. (2021). Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Genes. 12(8). 1178–1178. 21 indexed citations
20.
Terlizzi, Vito, et al.. (2019). Cystic fibrosis screen positive inconclusive diagnosis (CFSPID): Experience in Tuscany, Italy. Journal of Cystic Fibrosis. 18(4). 484–490. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annie Lu Breakdown of academic impact, for papers by Hsin‐Chun Huang Breakdown of academic impact, for papers by Sheila G. McKenzie Breakdown of academic impact, for papers by Rita Padoan Breakdown of academic impact, for papers by Hara Levy Breakdown of academic impact, for papers by T.J. Warke Breakdown of academic impact, for papers by Fabio Majo Breakdown of academic impact, for papers by Guillermo Suárez-Cuartín Breakdown of academic impact, for papers by Taşkın Yurtseven Breakdown of academic impact, for papers by Adèle Coriati
Rankless by CCL
2026